This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ephros, M.
Right arrow Articles by Zilberstein, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ephros, M.
Right arrow Articles by Zilberstein, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1999, p. 278-282, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Stage-Specific Activity of Pentavalent Antimony against Leishmania donovani Axenic Amastigotes

Moshe Ephros,1,2 Ari Bitnun,3 Pninit Shaked,3 Ella Waldman,3 and Dan Zilberstein3,*

Department of Pediatrics, Carmel Medical Center,1 and Faculty of Medicine,2 and Department of Biology,3 Technion-Israel Institute of Technology, Haifa, 32000, Israel

Received 21 August 1998/Returned for modification 28 September 1998/Accepted 5 November 1998

The standard treatment of human visceral leishmaniasis involves the use of pentavalent antimony (SbV) compounds. In recent years increasing numbers of clinical failures of treatment with SbV have been reported, probably due to the development of parasite resistance to this compound. The mode of action and mechanisms of resistance to SbV have not been fully elucidated. In the present study an axenic amastigote culture was used to study the in vitro responses of Leishmania donovani to SbV. Susceptibility to both sodium stibogluconate and meglumine antimoniate was found to be stage specific. Amastigotes were 73 to 271 times more susceptible to SbV than were promastigotes. As opposed to SbV, trivalent antimony (SbIII) was similarly toxic to both developmental stages. When promastigotes were transformed to amastigotes, susceptibility to meglumine antimoniate developed after 4 to 5 days, upon the completion of differentiation. In contrast, with transformation from amastigotes to promastigotes, resistance to meglumine antimoniate was acquired rapidly, within 24 h, before the completion of differentiation. The culture of promastigotes at an acidic pH (5.5) or at an elevated temperature (37°C) alone did not lead to the appearance of SbV susceptibility, emphasizing the requirement of both these environmental factors for the development of SbV susceptibility. A previously isolated sodium stibogluconate (Pentostam)-resistant L. donovani mutant (Ld1S.20) is also resistant to meglumine antimoniate, indicating cross-resistance to SbV-containing compounds. In contrast, no cross-resistance was found with SbIII, suggesting a mechanism of SbV resistance different from that described in Leishmania tarentolae. These data show that L. donovani susceptibility to SbV is parasite intrinsic, stage specific, and macrophage independent.

* Corresponding author. Mailing address: Department of Biology, Technion-Israel Institute of Technology, Haifa, 32000, Israel. Phone: 972-4-8293647. Fax: 972-4-8225153. E-mail: dzilbers{at}tx.technion.ac.il.

Antimicrobial Agents and Chemotherapy, February 1999, p. 278-282, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Vermeersch, M., da Luz, R. I., Tote, K., Timmermans, J.-P., Cos, P., Maes, L. (2009). In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences. Antimicrob. Agents Chemother. 53: 3855-3859 [Abstract] [Full Text]  
  • Martinez-Rojano, H., Mancilla-Ramirez, J., Quinonez-Diaz, L., Galindo-Sevilla, N. (2008). Activity of Hydroxyurea against Leishmania mexicana. Antimicrob. Agents Chemother. 52: 3642-3647 [Abstract] [Full Text]  
  • MITTAL, M. K., RAI, S., ASHUTOSH, , RAVINDER, , GUPTA, S., SUNDAR, S., GOYAL, N. (2007). CHARACTERIZATION OF NATURAL ANTIMONY RESISTANCE IN LEISHMANIA DONOVANI ISOLATES. Am J Trop Med Hyg 76: 681-688 [Abstract] [Full Text]  
  • Ashutosh, , Sundar, S., Goyal, N. (2007). Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143-153 [Abstract] [Full Text]  
  • Croft, S. L., Sundar, S., Fairlamb, A. H. (2006). Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev. 19: 111-126 [Abstract] [Full Text]  
  • Zhou, Y., Messier, N., Ouellette, M., Rosen, B. P., Mukhopadhyay, R. (2004). Leishmania major LmACR2 Is a Pentavalent Antimony Reductase That Confers Sensitivity to the Drug Pentostam. J. Biol. Chem. 279: 37445-37451 [Abstract] [Full Text]  
  • Verma, N. K., Dey, C. S. (2004). Possible Mechanism of Miltefosine-Mediated Death of Leishmania donovani. Antimicrob. Agents Chemother. 48: 3010-3015 [Abstract] [Full Text]  
  • Tempone, A. G., Perez, D., Rath, S., Vilarinho, A. L., Mortara, R. A., de Andrade, H. F. Jr (2004). Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 54: 60-68 [Abstract] [Full Text]  
  • Brochu, C., Wang, J., Roy, G., Messier, N., Wang, X.-Y., Saravia, N. G., Ouellette, M. (2003). Antimony Uptake Systems in the Protozoan Parasite Leishmania and Accumulation Differences in Antimony-Resistant Parasites. Antimicrob. Agents Chemother. 47: 3073-3079 [Abstract] [Full Text]  
  • Sudhandiran, G., Shaha, C. (2003). Antimonial-induced Increase in Intracellular Ca2+ through Non-selective Cation Channels in the Host and the Parasite Is Responsible for Apoptosis of Intracellular Leishmania donovani Amastigotes. J. Biol. Chem. 278: 25120-25132 [Abstract] [Full Text]  
  • Murray, H. W. (2001). Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197 [Full Text]  
  • Sereno, D., Holzmuller, P., Mangot, I., Cuny, G., Ouaissi, A., Lemesre, J.-L. (2001). Antimonial-Mediated DNA Fragmentation in Leishmania infantum Amastigotes. Antimicrob. Agents Chemother. 45: 2064-2069 [Abstract] [Full Text]  
  • Luque-Ortega, J. R., Rivero-Lezcano, O. M., Croft, S. L., Rivas, L. (2001). In Vivo Monitoring of Intracellular ATP Levels in Leishmania donovani Promastigotes as a Rapid Method To Screen Drugs Targeting Bioenergetic Metabolism. Antimicrob. Agents Chemother. 45: 1121-1125 [Abstract] [Full Text]  
  • Sereno, D., Roy, G., Lemesre, J. L., Papadopoulou, B., Ouellette, M. (2001). DNA Transformation of Leishmania infantum Axenic Amastigotes and Their Use in Drug Screening. Antimicrob. Agents Chemother. 45: 1168-1173 [Abstract] [Full Text]  
  • Frézard, F., Demicheli, C., Ferreira, C. S., Costa, M. A. P. (2001). Glutathione-Induced Conversion of Pentavalent Antimony to Trivalent Antimony in Meglumine Antimoniate. Antimicrob. Agents Chemother. 45: 913-916 [Abstract] [Full Text]  
  • Shaked-Mishan, P., Ulrich, N., Ephros, M., Zilberstein, D. (2001). Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania donovani. J. Biol. Chem. 276: 3971-3976 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»